Navigation Links
Greenberg Traurig Hosts Boston Healthcare Drinks and Discussion on China Biopharma Industry
Date:12/22/2018

On Wednesday, Dec. 12, Greenberg Traurig, LLP’s Boston office sponsored and hosted the Boston Healthcare Drinks event featuring Helen Chen, Greater China Managing Partner of L.E.K. Chen shared her insights on “Biopharma Business Opportunities Arising from China.”

The discussion was moderated by patent attorney David J. Dykeman, co-chair of Greenberg Traurig’s global Life Sciences & Medical Technology Group and co-chair of the firm’s Intellectual Property (IP) Group in Boston, and by Dr. Fang Xie, patent attorney and Boston office shareholder.

Prior to the program, Greenberg Traurig CEO Brian L. Duffy and Scott J. Bornstein, co-chair of the firm's Global Intellectual Property & Technology Practice and co-chair of the firm's Global Patent Litigation Group, welcomed guests, highlighting their recent trip to China and the firm's strong commitment to China and Asia in general. Greenberg Traurig has offices in Shanghai, China, and in Japan and Korea.

Since 2016, Greenberg Traurig has sponsored and hosted the Healthcare Drinks Boston Chapter in the firm’s Boston office. Healthcare Drinks provides a platform for management in the health care industry to meet, exchange ideas and socialize in a casual yet professional, educational and supportive atmosphere.

About Greenberg Traurig’s Life Sciences & Medical Technology Group: Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing. As part of the group, the Biotechnology and Pharmaceutical Industry Group focuses on advising clients in the biotechnology and pharmaceutical sectors.

About Greenberg Traurig’s Boston Office: Established in 1999, Greenberg Traurig’s Boston office is home to approximately 70 attorneys practicing in the areas of bankruptcy, corporate, emerging technology, energy, gaming, intellectual property, labor and employment, life sciences and medical technology, litigation, public finance, and real estate. An important contributor to the firm's international platform, the Boston office includes a team of nationally recognized attorneys with both public and private sector experience. The team offers clients the value of decades of legal experience and hands-on knowledge of the local business community, supported by the firm's vast network of global resources.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2018 Am Law Global 100. Web: http://www.gtlaw.com; Twitter: @GT_Law.

Read the full story at https://www.prweb.com/releases/greenberg_traurig_hosts_boston_healthcare_drinks_and_discussion_on_china_biopharma_industry/prweb16005946.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Albert Einstein College of Medicine hosts conference on Jewish genetic research
2. Accelrys Hosts Analyst Day, Updates Calendar Year 2013 Outlook
3. Mayo Clinic hosts NIH genomics director at Individualizing Medicine Conference
4. BGRF hosts inaugural 21st Century Medicine Forum
5. Montreal hosts International Union of Microbiology Societies congresses
6. Zombie ant fungi manipulate hosts to die on the doorstep of the colony
7. Zombie ant fungi know brains of their hosts
8. Boston Police Chief to Address Boston Marathon Bombings at IEEE Homeland Security Conference in Waltham, Mass., on 12 November
9. Boston Colleges Amir Hoveyda receives Italys Eni Award for Hydrocarbons Research
10. George Golumbeski, President of GRAIL, Inc. to Deliver Keynote at BD Boston 2018
11. Heart Health Innovator Boston Heart Diagnostics Joins American College of Lifestyle Medicine Corporate Roundtable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2019)... ... March 08, 2019 , ... Ace ... product, Well-Mints™ resveratrol + ribose hard candy lozenges ( http://www.well-mints.com ). , Well-Mints™ ... naturally flavored hard candy base dusted with powdered sugar. , Well-Mints'™ patented technology ...
(Date:3/1/2019)... (PRWEB) , ... February 28, 2019 , ... Teresa Krabbe, ... der Isar of the Technical University Munich, has been awarded an xCELLigence Research Grant ... an improved oncolytic virus platform. , Oncolytic viruses represent an exciting new ...
(Date:2/22/2019)... ... 2019 , ... RoosterBio, Inc, a privately held regenerative medicine ... Frederick, MD after a year of rapid growth. , “Hundreds of researchers and ... products to streamline their product development efforts in the regenerative medicine field, resulting ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... ... March 14, 2019 , ... Xybion ... research organizations. It is a low code, GDPR/21 CFR Part 11-compliant digital ... technology-driven automated data capture and seamless data and information management. , ...
(Date:3/11/2019)... ... ... In this live webinar, the featured speakers will focus on the many attributes that ... how to use the information they have from the protocol and clinical trial knowledge, ... is properly designed and set up to ensure flawless execution. As clinical trial success ...
(Date:3/9/2019)... SEATTLE (PRWEB) , ... March ... ... source for unbiased college rankings and higher education planning, announced the release ... identifies the top programs in the nation based on curriculum quality, program ...
(Date:3/4/2019)... ... ... of current hot topics through free webinars presented by leading experts in pharma, biotech, medical ... today to save your place! Participate in the discussion and stay relevant in your field! ... , March 20 – Implementing BYOD Across Phase II and III Clinical Trials ...
Breaking Biology Technology: